Cas:284472-92-0 tris[4-(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctyl)phenyl]phosphane manufacturer & supplier

Chemical Name:tris[4-(1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctyl)phenyl]phosphane

CAS.NO:284472-92-0

Synonyms:Tris[4-(heptadecafluorooctyl)phenyl]phosphine;Tris[4-(perfluorooctyl)phenyl]phosphine;MFCD03788382

Molecular Formula:C₄₂H₁₂F₅₁P

Molecular Weight:1516.44000

HS Code:

Physical and Chemical Properties:

Melting point:53-59ºC

Boiling point:575.9ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:13.59000

Exact Mass:1515.99000

LogP:19.84250

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:NONH for all modes of transpor

Packing Group:

Contact us for information like Tris[4-(heptadecafluorooctyl)phenyl]phosphine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD03788382 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Tris[4-(perfluorooctyl)phenyl]phosphine Use and application,Tris[4-(perfluorooctyl)phenyl]phosphine technical grade,usp/ep/jp grade.

Related News: The group, after examining Soliris’ late-stage trial data, determined they’re highly certain it produces a small benefit to patients who are positive for anti-AChR antibodies, while there’s a “moderate certainty of a small or substantial net health benefit.” (+/-)-4-(phenylmethoxy)-5,7-nonadienal manufacturers Meanwhile, EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization for Moderna’s Covid-19 vaccine, now known as Spikevax, to include adolescents 12 years of age and older. (+-)-15-Chlor-vincadifformin suppliers This scheme has a total outlay of Rs. 6,940 crore for the entire period. The applications under four different target segments were invited on November 30, 2020. Of the 215 applications, 36 products across the 4 target segments were granted. 10-acetylanthrone vendor & factory The group, after examining Soliris’ late-stage trial data, determined they’re highly certain it produces a small benefit to patients who are positive for anti-AChR antibodies, while there’s a “moderate certainty of a small or substantial net health benefit.” ,“This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.